XOMA Royalty Corporation has completed its acquisition of Mural Oncology plc via an Irish High Court–sanctioned scheme of arrangement, delivering $2.035 in cash per Mural share. The transaction became effective December 5, 2025, and Mural’s stock is being delisted from Nasdaq. The deal transfers full ownership of the company to XOMA, a buyer historically known for purchasing milestone and royalty streams rather than operating biotechs.
The strategic signal is hard to miss. By taking out a public oncology company outright, XOMA appears to be edging beyond pure royalty aggregation toward a hybrid model that can absorb, rationalize, and redeploy assets to maximize downstream economics. The move raises a timely question for capital-starved small caps: will royalty aggregators become consolidators of distressed innovation, using corporate control to curate pipelines and restructure licensing in a way that standalone issuers cannot?
The timing matters. Despite a modest thaw in biotech follow-ons, a long tail of micro-cap oncology companies remains stranded below cash with limited access to dilutive funding. In that environment, all-cash take-privates that promise certainty and speed can outcompete licensing one-offs or CVR-heavy wind-downs. For patients and investigators, the near-term issue is continuity: post-close decisions on which programs survive, get out-licensed, or are paused will dictate trial operations and site engagement. For payers, the end state could bring new counterparties but familiar products if assets are rehomed to larger sponsors. Competitors should assume that underloved programs may re-enter the market via structured partnerships, potentially changing the deal landscape in tumor types where Mural had been active.
This deal also fits a broader reshaping of biotech finance. Royalty and milestone monetization has matured into a mainstream asset class, and 2024–2025 saw a rise in nontraditional buyers using corporate control to capture optionality otherwise inaccessible through contract rights alone. Cross-border mechanisms like Irish schemes of arrangement are becoming playbook tools for taking out U.S.-listed, European-domiciled issuers efficiently, signaling that deal engineering is as important as scientific fit. As aggregator balance sheets scale, expect more direct acquisitions of public shells and stranded pipelines, not just piecemeal royalty buys.
Commercial and Medical Affairs teams should plan for the knock-on effects. If XOMA’s post-close approach emphasizes partnered, later-stage assets with line-of-sight to payer adoption, counterpart sponsors may face tight milestone gating tied to regulatory progress and real-world evidence generation. Medical Affairs leaders will be pressed to accelerate data packages that substantiate value claims in indications with crowded standards of care. Market Access teams should assume heightened scrutiny on indications with complex utilization management, where the risk-adjusted value of milestones and royalties can erode.
For business development leads across mid-cap pharma, the message is pragmatic: all-cash certainty can set the clearing price for distressed equities, and buyers with flexible mandates will use it to win scarce assets. The absence of a CVR here suggests a preference for clean exits and rapid portfolio decisions post-close, a useful datapoint as boards weigh strategic alternatives.
The next watch item is execution. Does XOMA retain, spin out, or relicense Mural’s programs, and how quickly does it translate control into milestone-bearing partnerships? If aggregators prove they can reliably rescue value from subscale public biotechs, the industry may be entering a phase where capital platforms—not traditional strategics—set the floor under innovation cycles. The open question for 2026: who becomes the next consolidator of last-mile oncology assets, and how will that reshape the bid-ask in early clinical dealmaking?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
